

Recommended Adult Immunization Schedule, United States, 2024*

Neil Murthy, MD, MPH, MSJ; A. Patricia Wodi, MD; Veronica V. McNally, JD; Matthew F. Daley, MD; and Sybil Cineas, MD; on behalf of the Advisory Committee on Immunization Practices†

In October 2023, the Advisory Committee on Immunization Practices (ACIP) voted to approve the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024. The 2024 adult immunization schedule, available at www.cdc.gov/vaccines/schedules/hcp/imz/adult.html, summarizes ACIP recommendations in the cover page, tables, notes, appendix, and addendum (Figure). The full ACIP recommendations for each vaccine are available at www.cdc.gov/vaccines/hcp/acip-recs/index.html. The 2024 schedule has also been approved by the director of the Centers for Disease Control and Prevention (CDC) and by the American College of Physicians (www.acponline.org), the American Academy of Family Physicians (www.aafp.org), the American College of Obstetricians and Gynecologists (www.acog.org), the American College of Nurse-Midwives (www.midwife.org), the American Academy of Physician Associates (www.aapa.org), the American Pharmacists Association (www.pharmacist.com), and the Society for Healthcare Epidemiology of America (www.shea-online.org).

The ACIP develops recommendations on the use of each vaccine after in-depth review of vaccine-related data, such as the epidemiology and burden of vaccine-preventable disease (VPD), vaccine efficacy and effectiveness, vaccine safety, quality of evidence, feasibility of program implementation, health equity impact, and economic analyses of immunization policy (1, 2). ACIP recommendations can be complex and challenging to implement. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist health care providers in implementing current ACIP recommendations. The use of vaccine trade names in this article and in the schedule is for identification purposes only and does not imply endorsement by the ACIP or CDC.

CHANGES TO THE 2024 ADULT IMMUNIZATION SCHEDULE

COVID-19 vaccination (3). The COVID-19 vaccination section was updated to reflect the new COVID-19 vaccination recommendations that were approved during an ACIP public meeting held on 12 September

2023. All adults are now recommended to receive at least 1 dose of the updated (2023–2024 Formula) COVID-19 vaccine. The “Routine vaccination” section describes the vaccine recommendations for the general population, while the “Special situations” section describes the vaccine recommendations for persons who are moderately or severely immunocompromised. The number of doses needed and intervals between doses may vary based on a patient’s immunization history, their immunocompromised status, and the vaccine product used.

Haemophilus influenzae type b (Hib) vaccination. Recommendations for Hib vaccination have not changed.

Hepatitis A (HepA) vaccination (4). Minor changes were made to the “Routine vaccination” and “Special situations” sections to improve clarity in the language.

Hepatitis B (HepB) vaccination (5). Additional context was provided in the “Routine vaccination” section to describe the risk-based recommendation for persons 60 years of age and older. The text now reads, “Age 60 years or older *without* known risk factors for hepatitis B virus infection *may* receive a HepB vaccine series. Age 60 years or older *with* known risk factors for hepatitis B virus infection *should* receive a HepB vaccine series. Any adult age 60 years of age or older who requests HepB vaccination should receive a HepB vaccine series.” A note was added at the end of the “Routine vaccination” section describing the shared clinical decision-making recommendation for persons 60 years of age and older with diabetes.

Human papillomavirus (HPV) vaccination (6). Guidance on interrupted schedules was removed because that information is presented on the cover page. To add clarity, the words “of any valency” were added to the bullet “No additional dose recommended when any HPV vaccine series *of any valency* has been completed using the recommended dosing intervals.” Lastly, a resource was added to assist health care providers

See also:

Editorial comment. 253

This article was published at [Annals.org](https://annals.org) on 12 January 2024.

* The 2024 adult immunization schedule appeared in *Annals of Internal Medicine* and on the Centers for Disease Control and Prevention website at www.cdc.gov/vaccines/schedules. An announcement summarizing changes to the 2024 adult immunization schedule was published in the *Morbidity and Mortality Weekly Report* on 12 January 2024. Readers can cite the 2024 adult immunization schedule as follows: Murthy N, Wodi AP, McNally VV, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2024. *Ann Intern Med*. Epub 12 Jan 2024. doi:10.7326/M23-3269

† The 2024 adult immunization schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and was prepared by the ACIP Combined Immunization Schedule Work Group; Neil Murthy (Centers for Disease Control and Prevention, Atlanta, Georgia); A. Patricia Wodi (Centers for Disease Control and Prevention, Atlanta, Georgia); Veronica V. McNally (Franny Strong Foundation, West Bloomfield, Michigan); Matthew F. Daley (Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado); and Sybil Cineas (The Warren Alpert Medical School of Brown University, Providence, Rhode Island). For a list of members of the ACIP and the ACIP Combined Immunization Schedule Work Group, see Appendix A (available at [Annals.org](https://annals.org)).